The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Modulating the immune microenvironment to enhance T-cell engager activity in multiple myeloma
Paola Neri, MD, PhD, University of Calgary, Calgary, Canada, discusses the role of immune composition and the bone marrow microenvironment in response to T-cell-engaging therapies in multiple myeloma. She highlights how immunomodulatory agents such as pomalidomide and iberdomide may help overcome immunosuppression and improve T-cell function, potentially enhancing the activity and persistence of BCMA- and GPRC5D-directed therapies. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
